Results 1 to 10 of about 345,959 (307)
Adjuvant Therapy: Melanoma [PDF]
Journal of Skin Cancer, 2011 With an incidence that is increasing at 2–5% per year, cutaneous melanoma is an international scourge that disproportionately targets young individuals. Despite much research, the treatment of advanced disease is still quite challenging.
Diwakar Davar +2 more
doaj +3 more sources
Real-world efficacy of postoperative adjuvant EGFR-TKI therapy for stage IA2-IA3 lung adenocarcinoma with high-risk pathological factors [PDF]
World Journal of Surgical OncologyBackground The role of EGFR-TKIs as adjuvant therapy for stage IA lung adenocarcinoma after surgery remains controversial. Though 5-year OS of stage IA patients reaches 88%, the 5-year DFSs of IA1, IA2, and IA3 vary a lot, 88.2%, 73.6% and 64.5 ...
Sida Lu +6 more
doaj +2 more sources
Reliability of Reconstructed Breast Flap after Chemotherapy and Radiotherapy in Immediate Breast Reconstruction [PDF]
Archives of Plastic Surgery, 2012 Background Postmastectomy adjuvant therapy is used to prevent locoregional recurrence and improve overall breast cancer specific survival rates. However, it can adversely affect the cosmetic results of reconstruction.
Keun-Cheol Lee +10 more
doaj +2 more sources
Neoadjuvant and Adjuvant Therapy for Renal Cell Carcinoma
Société Internationale d’Urologie Journal, 2022 Patients undergoing definitive surgery or ablative techniques for nonmetastatic kidney cancer have varying degrees of risk of recurrent disease post procedure.
Naomi B. Haas +8 more
doaj +1 more source
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. [PDF]
PLoS ONE, 2015 The management of pT1a-b pN0 HER2-positive breast cancer is controversial and no data about the efficacy of trastuzumab in this setting are available from randomized clinical trials.
Stefania Gori +35 more
doaj +1 more source
Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer
Medicine, 2022 . Deciding if patients with small (≤1 cm), node-negative, human epidermal growth factor receptor 2 (HER2) positive breast cancer should receive adjuvant systemic therapy remains a challenge.
Xuan Yang, MM, Chong Xiao Qu, MD
doaj +1 more source
The Cancer Journal, 2016 In 2015, ramucirumab and TAS-102 became the 10th and 11th drugs approved by the Food and Drug administration for the treatment of patients with colorectal cancer, not counting leucovorin, and yet only 3 agents, 5-fluorouracil, capecitabine, and oxaliplatin, have proven benefit in adjuvant treatment.
Carling, Ursem +2 more
openaire +2 more sources
Adjuvant Dermatological Therapy
JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 2021 não ...
Sociedade Brasileira de TMO SBTMO +2 more
openaire +2 more sources
Frontiers in Oncology, 2023 BackgroundCholangiocarcinoma (CCA) is a highly heterogeneous malignant tumor, and more than 60% of patients have recurrence and metastasis after surgery. The efficacy of postoperative adjuvant therapy for CCA remains unclear.
Zhongquan Sun +60 more
doaj +1 more source